Abstract: Objective To explore the clinical characteristics and prognostic factors of patients with cutaneous melanoma. Methods A total of 74 cutaneous melanoma patients treated in Nanjing Drum Tower Hospital from January 2010 to June 2016 were enrolled. All patients received operation in this study. According to adjuvant therapy after operation， patients were divided into two groups： patients with or without immunotherapy. Immunotherapy included adoptive T-cell transfer and cytokine therapy. Patients without immunotherapy consisted of patients without therapy and patients with only radiotherapy or chemotherapy after operation. We retrospectively collected clinicopathological data in order to calculate survival and identify the main prognostic factors using Cox proportional hazards regression model. Results Median overall survival （OS） and diseasefree survival （DFS） of all patients were 32.0 months （95％CI： 20.2-43.8） and 23.0 months （95％CI： 16.4-29.6）， respectively. For patients of stage Ⅲ， the median OS was extended in those receiving immunotherapy followed by surgery than those without combined immunotherapy（38.0 months vs. 10.0 months， P=0.002）. In multivariate analysis， age， clinical stage， lymph node metastasis, ulceration and Breslow thickness were significant prognostic factors for OS. In addition， clinical stage, lymph node metastasis, ulceration and Breslow thickness were significant prognostic factors for DFS. Conclusion The age， clinical stage, lymph node metastasis, Breslow thickness and ulceration were associated with prognosis of patients with cutaneous melanoma. Postoperative combined immunotherapy can prolong the OS of patients with stage Ⅲ.